Many promising startups applied for this year's Investors Forum and 12 selected companies delivered their pitch to present their company to interesting partners and discuss their business strategy, technology direction and capital-raising plan. On stage of the 20th edition of the Dutch Life Sciences conference, Stijn Heessen, COO of Alder Therapeutics became the proud winner of the Investors Forum and was awarded a partnering ticket with a total value of €2,500 and a half day Booster Session offered by PwC.
About Alder Therapeutics
Established in 2022, Alder Therapeutics is a Swedish private pre-clinical stage stem cell therapy development company with two promising allogeneic programs in the pipeline with preclinical proof of concept data showing they can treat disease in relevant large animal models.
Their first and most advanced program ALD01 is a retinal cell therapy to treat Retinitis Pigmentosa (RP), a debilitating inherited blindness disease affecting 1 in 4,000 people worldwide. Current treatments for RP are limited to one single-mutation gene therapy with few eligible patients. For the others, there are no treatment options. ALD01 could revolutionize RP treatment, offering a mutation agnostic option for almost all patients.
Their second program ALD02 is a cardiac cell therapy for patients suffering from heart failure. Current treatments options are often invasive and/or expensive, or just treat the symptoms. ALD02 is aimed at regenerating damaged heart tissue in those patients through non-invasive administration of stem cell-derived heart muscle cells.
Alder Therapeutics is a seasoned agile team of company builders and global cell therapy experts all focused on bringing Alder’s unique therapy options to patients. Backed by Swedish investors Flerie and Linc, they are now looking for an active lead investor to help take their lead program ALD01 to the clinical stage in 2027.
Investors Forum
The Investors forum is an exciting opportunity for young life sciences companies that have not reach the series A financing stage and looking for equity capital and/or partnerships. The forum offers excellent opportunities for presenting your company to Venture Capitalists, corporate- and regional investment funds and discuss your business strategy.
If you are interested in participating in the Investors Forum on December 11, 2025, please contact Miranda de Regt at miranda.de.regt@dutchlifesciences.com.